Medicus Pharma Ltd.
For the period ended Dec 31, 2024. Filed Mar 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 28, 2025
MDCX$1.89+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Shareholders' Equity
| Common shares · Additionalpaid-in capital · Accumulateddeficit · Total | |||||
|---|---|---|---|---|---|
| # | $ | $ | $ | $ | |
| Balance as of December 31, 2022 | 1,884,900 | 194,538 | - | (12,383,622) | (12,189,084) |
| Issuance of common shares upon acquisition of Interactive Capital Partners Ltd. | 287,471 | - | - | (50,000) | (50,000) |
| Issuance of common shares upon conversion of preferred shares | 3,952,366 | 10,506,903 | - | - | 10,506,903 |
| Issuance of common shares upon conversion of promissory notes | 647,224 | 2,799,859 | - | - | 2,799,859 |
| Issuance of common shares upon conversion of note payable | 27,286 | 150,000 | - | - | 150,000 |
| Issuance of common shares in connection with financing | 1,277,426 | 5,109,950 | - | - | 5,109,950 |
| Stock-based compensation | - | - | 98,585 | - | 98,585 |
| Net loss and comprehensive loss for the year | - | - | - | (5,314,765) | (5,314,765) |
| Balance as of December 31, 2023 | 8,076,673 | 18,761,250 | 98,585 | (17,748,387) | 1,111,448 |
| Issuance of common shares upon conversion of debt | 1,308,798 | 5,210,962 | - | - | 5,210,962 |
| Issuance of common shares in connection with a private placement, net of issuance costs of $375,000 | 1,461,250 | 5,470,000 | - | - | 5,470,000 |
| Issuance of common shares and warrants in connection with initial public offering, net of issuance costs of $2,218,014 | 970,000 | 1,075,983 | 708,708 | - | 1,784,691 |
| Stock-based compensation | - | - | 713,119 | - | 713,119 |
| Net loss and comprehensive loss for the year | - | - | - | (11,155,516) | (11,155,516) |
| Balance as of December 31, 2024 | 11,816,721 | 30,518,195 | 1,520,412 | (28,903,903) | 3,134,704 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.